key: cord-0965357-c626qlly
authors: Sookaromdee, Pathum; Wiwanitkit, Viroj
title: Acetylsalicylic Acid and COVID-19 Prevention: A Comment
date: 2021-06-30
journal: Clin Appl Thromb Hemost
DOI: 10.1177/10760296211027660
sha: 2b3eb7cc112845e7c623237c94c2b0212d7bedc0
doc_id: 965357
cord_uid: c626qlly

nan

We would like to share ideas on "Could low doses acetylsalicylic acid (ASA) prevent thrombotic complications in COVID-19 patients?" 1 Cacciapuoti and Cacciapuoti noted that "adult individuals receiving low ASA doses and nowadays affected by SARS-CoV-2, could be protected against possible inflammatory and thrombotic complications." 1 Cacciapuoti and Cacciapuoti discussed on inhibition of platelet aggregability by low dose ASA. 1 We agree for the proposed biomechanism. Nevertheless, we would like to draw attention to another side of the coin.

In COVID-19, thrombocytopenia is observed. 2 Hemorrhagic complication in COVID-19 is considered as an important clinical problem. 3 A basic question is whether ASA can cause unwanted adverse effect bleeding. Referring to another wellknown viral disease, dengue, an immune thrombocytopenia occurs and using ASA can cause hemorrhagic complication. Whether the similar problem will occur if ASA is used for prevention of thrombotic complications in COVID-19 is an important clinical consideration. The immune thrombocytopenia is reported in COVID-19 2 and should not be forgotten.

Pathum Sookaromdee https://orcid.org/0000-0002-8859-5322

Could low doses acetylsalicylic acid prevent thrombotic complications in COVID-19 patients?

Mechanism of thrombocytopenia in COVID-19 patients

Hemorrhagic problem among the patients with COVID-19: clinical summary of 41 Thai infected patients